Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 287 of the 288 references it cites were found in a registry or an index.

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Open access
de Man, Femke M., Goey, Andrew K. L., van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander · 2018 · Clinical Pharmacokinetics

Abstract

Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokinetic variability. Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 1000-fold more active compared with irinotecan itself. Several phase I and II enzymes, including cytochrome P450 (CYP) 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A, are involved in the formation of inactive metabolites, making its metabolism prone to environmental and genetic influences. Genetic variants in the DNA of these enzymes and transporters could predict a part of the drug-related toxicity and efficacy of treatment, which has been shown in retrospective and prospective trials and meta-analyses. Patient characteristics, lifestyle and comedication also influence irinotecan pharmacokinetics. Other factors, including dietary restriction, are currently being studied. Meanwhile, a more tailored approach to prevent excessive toxicity and optimize efficacy is warranted. This review provides an updated overview on today's literature on irinotecan pharmacokinetics, pharmacodynamics, and pharmacogenetics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-018-0644-7

Cites

287 of 287 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 pH-dependent equilibrium of irinotecan and SN-38 isoforms
Fig. 1 pH-dependent equilibrium of irinotecan and SN-38 isoformsCC BY-NC · PubMed Central
Fig. 2 Irinotecan metabolism and excretion. The main excretion routes of all metabolites are depicted. * Active metabolite. CES carboxylesterase, BES butyrylcholinesterase, CYP cytochrome P450 enzymes, UGT uridine diphosphate glucuronosyltransferase, β-gluc β-glucuronidase
Fig. 2 Irinotecan metabolism and excretion. The main excretion routes of all metabolites are depicted. * Active metabolite. CES carboxylesterase, BES butyrylcholinesterase, CYP cytochrome P450 enzymes, UGT uridine diphosphate glucuronosyltransferase, β-gluc β-glucuronidaseCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 288 references

Research works printed but not linked: 5

  1. Okamoto H, Nagatomo A, Kunitoh H, Kunikane H, Watanabe K. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 1998;82(11):2166–72. · doi:10.1002/(sici)1097-0142(19980601)82:11<2166::aid-cncr11>3.0.co;2-s
  2. National Institutes of Health. Common terminology criteria for adverse events (CTCAE). Bethesda: National Institutes of Health; 2010.
  3. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, et al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer. 2001;92(2):269–75. · DOI
  4. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer. 1999;85(11):2375–84. · doi:10.1002/(sici)1097-0142(19990601)85:11<2375::aid-cncr12>3.0.co;2-e
  5. Murphy BA, Cmelak A, Burkey B, Netterville J, Shyr Y, Douglas S, et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (Williston Park). 2001;15(7 Suppl 8):47–52.

Cited by

See all 439

Metadata

Authors
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S.
Affiliations
  • Erasmus MC (NL)
  • Erasmus MC Cancer Institute (NL)
Corresponding author
Bins, Sander
Venue
Clinical Pharmacokinetics
Published
2018-03-08
Volume
57
Issue
10
Pages
1229-1254
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2790768119
Cited by
421
References
288
Citations by year
2026: 41 · 2025: 51 · 2024: 58 · 2023: 69 · 2022: 63 · 2021: 67 · 2020: 41 · 2019: 22 · 2018: 8
FWCI
6.70
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0 (tdm)
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
irinotecan, pharmacokinetics, pharmacodynamics, pharmacogenetics, SN-38, carboxylesterase, CYP3A4, UGT1A, topoisomerase I inhibitor, dose-limiting toxicity, interindividual variability, drug metabolism, genetic variants
MeSH terms
Irinotecan, UGT1A1 Enzyme, Drug Interactions, Humans, Inactivation, Metabolic, Tissue Distribution, Glucuronosyltransferase, Area Under Curve, Polymorphism, Single Nucleotide, Cytochrome P-450 CYP3A, Precision Medicine, Topoisomerase I Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. https://app.cochat.ai/papers/10.1007/s40262-018-0644-7
The paper
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018). Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-018-0644-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.